AskVet
Website: https://askvet.app/
AskVet is the leading AI and data-driven technology company in animal health. We use AI and our proprietary companion animal and livestock data to build highly intelligent veterinary agents that will join the workforce – enhancing engagement, improving efficiency, and supporting revenue growth for animal health organizations.
In 2023, AskVet introduced VERA (Veterinary Engagement & Relationship Agent), the world’s only AI veterinarian. VERA is trained on over 2.5 million recorded conversations between veterinarians and animal owners, curricula from six veterinary colleges, and more than 180 curated medical, nutritional, and behavioral data sets. She currently converses in 50 languages.
As a customizable conversational AI, VERA powers medical triage, operational support, customer acquisition, sales, retention, and back-end automation – making her an invaluable asset across the animal health ecosystem.
Demand in the US for animal health care for both companion animals and food production animals is outpacing supply of qualified veterinarians and technicians. The US animal health industry needs to use data and AI to augment and expand the available supply of human veterinary expertise to close the supply and demand gap. And the problem is much worse if you look at the global growth of companion and food production animals. AskVet has created a suite of data/AI products on the VERA platform where companion and food animal businesses can use their propriety data and VERA’s veterinary expertise to create differentiation and competitive advantage.
Steve Worland
CEO
Atomwise
Steve Worland, Ph.D. serves as the CEO of Atomwise and has over 30 years of experience in corporate leadership and pharmaceutical R&D. He was previously President, CEO, and Board Member of eFFECTOR Therapeutics, which he co-founded in 2012. Prior to that, he was CEO of Anadys Pharmaceuticals, where he led the company through its acquisition by Roche in 2011. Before becoming CEO, he served as Chief Scientific Officer and President of Pharmaceuticals at Anadys.
Earlier in his career, he held senior positions at Agouron Pharmaceuticals, Warner-Lambert, and Pfizer, where his scientific research contributed to the discovery and development of Paxlovid (nirmatrelvir), Inlyta (axitinib), zotatifin, tomivosertib, and other clinical-stage candidates. At Agouron, he was Vice President and Director of Molecular Biology and Biochemistry, remaining at the company through its acquisitions.
Dr. Worland earned a Ph.D. in Chemistry from the University of California, Berkeley, and completed a postdoctoral fellowship in Molecular Biology at Harvard University as an NIH fellow. He earned a B.S. with Highest Honors in Biological Chemistry from the University of Michigan. He serves on the Board of Directors at Blacksmith Medicines and has previously served on the boards of Tracon Pharmaceuticals, Forge Therapeutics, and GenMark Diagnostics.
Joon Chung
VP- IP & Legal
Amicus Therapeutics
Chloe Jiang
Managing Assistant General Counsel
Novo Nordisk
Kristie Baisden
Medical Director, Women’s Healthcare
Bayer